Tiziana Life Sciences PLC (LON:TILS)(NASDAQ:TLSA) has announced plans to begin a clinical study of its nasally administered Foralumab in COVID-19 patients in Brazil. Proactive analyst Emma Ulker talks to Katie Pilbeam about the trial which will begin shortly with clinical data potentially available before the end of the year. Ulker says the rationale, delivery approach and data are very promising and clearly require substantiation in COVID-19 patients.
Price: 147 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE
FTSE 100 opened with a jump in the first trading day of the new year although coronavirus infections continue to surge. London’s main index added 120 points to 6,580 in early trading. The UK has begun the rollout of the COVID-19 vaccine produced by AstraZeneca PLC (LON:AZN) and Oxford...
Retail & consumer
Retail & consumer
Retail & consumer
Industry & services
